CVS HEALTH Corp 8-K

What Happened CVS Health filed an 8‑K on May 18, 2026 reporting the results of its 2026 Annual Meeting of Stockholders held May 14, 2026. Stockholders elected all 13 director nominees for one‑year terms, ratified Ernst & Young LLP as the company’s independent auditor for 2026, approved an advisory (non‑binding) “say‑on‑pay” vote, and approved the company’s new 2026 Incentive Compensation Plan (the 2026 ICP), which replaces the expiring 2017 plan and applies to awards granted after May 14, 2026. A shareholder proposal to lower the threshold for stockholder written consents was not approved.

Key Details

• Quorum: 1,142,802,406 shares present in person or by proxy.
• Directors: All 13 nominees elected (individual vote counts reported in the filing).
• Auditor ratification: Ernst & Young LLP ratified — 1,117,411,640 for, 24,102,167 against, 1,288,599 abstained.
• Say‑on‑pay: Advisory approval — 976,252,194 for, 59,088,923 against, 3,377,357 abstained (104,083,932 broker non‑votes).
• 2026 ICP: Approved — 1,006,709,390 for, 28,851,289 against, 3,157,795 abstained; replaces the 2017 Incentive Compensation Plan and governs awards after May 14, 2026.
• Shareholder proposal on written consent threshold: Not approved — 417,969,177 for vs. 617,361,014 against.

Why It Matters Approving the 2026 Incentive Compensation Plan is material because it governs future equity and incentive awards to executives and employees, which can affect dilution, executive pay mix, and alignment of management incentives with shareholder interests. Ratifying the auditor maintains continuity in financial oversight. Reelecting the full slate of directors keeps the existing board composition intact. The rejection of the shareholder written‑consent proposal signals that a majority of votes favored maintaining the current governance threshold.